XML 45 R34.htm IDEA: XBRL DOCUMENT
v3.24.3

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables) | 6 Months Ended
--- | ---
Sep. 28, 2024
Segment Reporting [Abstract] |
Selected Information by Business Segment | Selected information by reportable segment is presented below:
| Three Months Ended |  | Six Months Ended
(In thousands) | September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Net revenues(1) |  |  |  |  |  |  |
Plasma | $ | 138,565 |  |  | $ | 142,643 |  |  | $ | 274,607 |  |  | $ | 282,134 |
Blood Center | 68,804 |  |  | 70,470 |  |  | 135,643 |  |  | 139,639 |
Hospital | 138,384 |  |  | 105,950 |  |  | 272,790 |  |  | 208,378 |
Net revenues in constant currency | 345,753 |  |  | 319,063 |  |  | 683,040 |  |  | 630,151 |
Effect of exchange rates | (242) |  |  | (880) |  |  | (1,357) |  |  | (636) |
Net revenues | $ | 345,511 |  |  | $ | 318,183 |  |  | $ | 681,683 |  |  | $ | 629,515 |
(1) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
| Three Months Ended |  | Six Months Ended
(In thousands) | September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Segment operating income |  |  |  |  |  |  |
Plasma | $ | 69,728 |  |  | $ | 78,042 |  |  | $ | 135,565 |  |  | $ | 153,740 |
Blood Center | 27,167 |  |  | 27,307 |  |  | 49,789 |  |  | 53,590 |
Hospital | 59,705 |  |  | 41,834 |  |  | 113,596 |  |  | 82,777 |
Segment operating income | 156,600 |  |  | 147,183 |  |  | 298,950 |  |  | 290,107 |
Corporate expenses (1) | (74,407) |  |  | (75,750) |  |  | (144,387) |  |  | (151,059) |
Effect of exchange rates | 1,312 |  |  | (3,091) |  |  | (37) |  |  | (478) |
Amortization of acquired intangible assets | (12,264) |  |  | (7,222) |  |  | (24,735) |  |  | (14,695) |
Amortization of fair value inventory step-up | (3,739) |  |  | — |  |  | (8,978) |  |  | — |
Integration and transaction costs | (882) |  |  | (1,784) |  |  | (13,205) |  |  | (2,899) |
Restructuring costs | (4,792) |  |  | (86) |  |  | (9,414) |  |  | (75) |
Restructuring related costs | (1,571) |  |  | (1,947) |  |  | (4,089) |  |  | (4,151) |
Digital transformation costs | (4,858) |  |  | (3,592) |  |  | (11,203) |  |  | (7,297) |
PCS2 related charges | — |  |  | (552) |  |  | — |  |  | (411) |
MDR and IVDR costs | (991) |  |  | (1,988) |  |  | (2,117) |  |  | (3,154) |
Litigation-related charges | (320) |  |  | (5,449) |  |  | (1,075) |  |  | (6,507) |
Impairment of intangible assets | (2,391) |  |  | (10,419) |  |  | (2,391) |  |  | (10,419) |
Gain on sale of property, plant and equipment | — |  |  | — |  |  | 14,134 |  |  | — |
Operating income | $ | 51,697 |  |  | $ | 35,303 |  |  | $ | 91,453 |  |  | $ | 88,962 |
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
Schedule of Revenues by Business Unit and Geographic Regions | Net revenues by business unit are as follows:
|  | Three Months Ended |  | Six Months Ended
(In thousands) | September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
| Plasma | $ | 138,561 |  |  | $ | 142,794 |  |  | $ | 274,471 |  |  | $ | 282,415 |
| Apheresis | 54,332 |  |  | 54,973 |  |  | 103,426 |  |  | 104,139 |
| Whole Blood | 14,196 |  |  | 14,683 |  |  | 31,347 |  |  | 34,723 |
| Blood Center | 68,528 |  |  | 69,656 |  |  | 134,773 |  |  | 138,862 |
| Interventional Technologies(1) | 61,923 |  |  | 38,541 |  |  | 124,967 |  |  | 76,161 |
| Blood Management Technologies(2) | 76,499 |  |  | 67,192 |  |  | 147,472 |  |  | 132,077 |
| Hospital | 138,422 |  |  | 105,733 |  |  | 272,439 |  |  | 208,238 |
Net revenues(3) | $ | 345,511 |  |  | $ | 318,183 |  |  | $ | 681,683 |  |  | $ | 629,515 |
(1) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.
(2) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
(3) Beginning in fiscal 2025, the Company integrated service revenue within its three business units. Prior periods were conformed to current presentation.
Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:
| Three Months Ended |  | Six Months Ended
(In thousands) | September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
United States | $ | 256,061 |  |  | $ | 236,345 |  |  | $ | 504,963 |  |  | $ | 473,418 |
Japan | 16,424 |  |  | 15,011 |  |  | 30,129 |  |  | 26,784 |
Europe | 41,991 |  |  | 38,666 |  |  | 89,216 |  |  | 78,053 |
Rest of Asia | 25,768 |  |  | 27,735 |  |  | 45,551 |  |  | 49,775 |
Other | 5,267 |  |  | 426 |  |  | 11,824 |  |  | 1,485 |
Net revenues | $ | 345,511 |  |  | $ | 318,183 |  |  | $ | 681,683 |  |  | $ | 629,515 |

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration